- Positive Phase 2 topline results for RAP-219 in bipolar mania; two Phase 3 trials planned for 2H 2027.
- Q3 2026 net loss expanded to $40.2M ($0.84/share) vs $26.9M ($0.71/share) prior year.
- Strong liquidity of $815.4M as of Nov 3, providing projected cash runway through end of 2029.
Signal #128862 · SEC 8-K
$RAPP SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $RAPP filing catalyst
Why did $RAPP trigger an AI stock catalyst alert?
$RAPP triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +4.5/10). Headline: Rapport Therapeutics Reports Positive RAP-219 Phase 2 Data, Runway to 2029. Key points: - Positive Phase 2 topline results for RAP-219 in bipolar mania; two Phase 3 trials planned for 2H 2027. - Q3 2026 net loss expanded to $40.2M ($0.84/share) vs $26.9M ($0.71/share) prior year. - Strong liquidity of $815.4M as of Nov 3, providing projected cash runway through end of 2029.
How did $RAPP stock react after the SEC filing?
After the SEC 8-K for $RAPP, observed market reaction: T0 price $25.44. Past moves do not guarantee future results.
Where can I get real-time $RAPP SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $RAPP via Telegram and the VIP Web Terminal from €10/month.